Press Release

PertADO Trial to Evaluate Pertagen™, a New Recombinant Pertussis Vaccine in Adolescents in Switzerland

The Geneva University Hospitals in Switzerland is conducting the PertADO Geneva Trial, the first clinical study in Europe evaluating Pertagen™, a new recombinant acellular pertussis vaccine.

Pertagen™ is BioNet-Asia’s acellular pertussis vaccine containing genetically-inactivated Pertussis Toxin (PTgen). Thisis the only monovalent recombinant pertussis vaccine in the world, approved in Asia for a booster indication in adolescents and adults.

GENEVA, 15 May, 2017 - The Geneva University Hospitals (HUG) and BioNet-Asia are announcing that they have recently completed the 28-day safety follow-up of the PertADO Geneva Trial, a Phase II study in Switzerland evaluating Pertagen™, a recombinant pertussis vaccine. The study aims to compare the safety and immunogenicity induced by booster vaccination with acellular pertussis vaccines including chemically or genetically-detoxified Pertussis Toxin (PT) in adolescents previously immunized with acellular pertussis vaccines. Half of the study participants received one dose of recombinant aP vaccine plus a tetanus-diphtheria booster vaccine, and the other half a comparator licensed Tdap vaccine containing a chemically detoxified PT. No safety issues have been reported in any of the study participants during the follow-up period. The next step will be to measure and compare immune responses induced by the two vaccines.

Pertussis, or whooping cough, is a highly contagious respiratory illness that has been on the rise in a number of countries around the world. The disease is caused by the bacterium Bordetella pertussis whose major virulent factor is the pertussis toxin. Immunity acquired through vaccination or infection is short-lived and requires repeated boosting at regular time points. An unprecedented global demand for pertussis vaccine has exhausted vaccine supplies in recent years. BioNet’s recombinant DNA technology produces more native and active PT than the ones included in currently available chemically detoxified acellular pertussis vaccines.

Professor Claire-Anne Siegrist, Director of the Center of Vaccinology of HUG, and responsible for the PertADO trial said: We are very pleased to have successfully completed the first stage of this study with the recruitment of the participants and the safety follow up. We are now keen to evaluate the immunogenicity of this recombinant acellular pertussis vaccine booster, tested for the first time in adolescents previously immunized with five doses of conventional acellular pertussis vaccines. A monovalent recombinant pertussis vaccine, not formulated with other antigens, could represent a very interesting alternative solution to conventional Tdap vaccines when only boosting pertussis immunity is sought or needed.”

Dr. Pham Hong Thai, Chief Executive Officer of BioNet-Asia, said: “We are delighted to collaborate with the Geneva University Hospitals on this study as this is the first time that our recombinant pertussis vaccine takes part in a clinical trial in Europe. Given the safety and superior immunogenicity of Pertagen™ as demonstrated in previous trials, this study in Switzerland represents the first step towards bringing a novel acellular pertussis vaccine to Europe to address waning immunity and pertussis resurgence.”

About Geneva University Hospitals and the PertADO trial

The Geneva University Hospitals (HUG), reference academic institution at both national and international level, gather eight public hospitals of Geneva. Its Center of Vaccinology, led by Professor Claire-Anne Siegrist, gained international recognition through the performance of a large first-in-humans Phase I randomized clinical trial that enrolled 115 subjects to characterize the safety and immunogenicity of the VSV-ZEBOV Ebola vaccine candidate.

With their 10,500 employees, the HUG welcome each year 60,000 hospitalized patients and assure 91,000 emergencies, 990,000 consultations or ambulatory care and 26,000 surgical procedures. More than 800 physicians, 3,000 interns and 150 apprentices perform their training here. The HUG are working closely with the Faculty of Medicine of the University of Geneva and WHO in various training and research projects. They develop partnerships with CHUV, EPFL, CERN and other actors from the Lemanic Health Valley. More information on: www.hug-ge.ch

The PertADO Geneva Trial is a phase II, randomized double-center, and observer-blind controlled pilot vaccine trial in 11 to 15 years old healthy subjects to assess the safety and immunogenicity of the genetically inactivated pertussis toxin included in a novel acellular pertussis vaccine manufactured by BioNet-Asia when delivered by the intramuscular route to adolescents previously primed and boosted with chemically-inactivated PT, along with Td vaccine and in comparison with that of a licensed Tdap vaccine. More information at ClinicalTrials.gov Identifier: NCT02946190.

About BioNet-Asia

BioNet-Asia Co. Ltd offers access to vaccine and technology through biotech innovation and partnering networks. BioNet has built several international partnerships fostering vaccine self-reliance and leading to the supply of billions of doses of vaccines worldwide. BioNet has also a broad pipeline of vaccines in R&D and clinical stages. In December 2016 BioNet received Marketing Authorization Approval from the Thai Food and Drug Administration for its monovalent recombinant acellular Pertussis (aP) vaccine Pertagen™ and Tetanus-diphtheria-acellular Pertussis (TdaP) combination vaccine Boostagen™. BioNet’s new generation pertussis vaccines are produced from a proprietary Bordetella pertussis strain expressing genetically-detoxified Pertussis Toxin (PTgen). The unique properties of BioNet PTgen enables the vaccine to induce superior anti-PT immune response, as successfully demonstrated in clinical trials in adolescents and adults.

About Pertagen

Current licensed acellular pertussis vaccines are inactivated by the use of chemicals that make Pertussis Toxin (PT), the principal antigen present in all acellular pertussis vaccines, loose its natural structure. This affects the ability of vaccine induced antibodies to effectively recognize and neutralize native toxin produced at the time of infection. BioNet has patented a recombinant DNA technology to produce a genetically-inactivated PT where the structure and PT-neutralizing epitopes remain preserved and that elicits highly functional antibodies.

Pertagen™ is a recombinant acellular pertussis vaccine, licensed in Thailand for active booster immunization against pertussis in individuals from the age of 11 years onwards. Pertagen™ may be considered as an alternative to combined tetanus, diphtheria and acellular pertussis vaccines in persons having received multiple and frequent tetanus and diphtheria vaccine doses in the past.

 

Geneva University Hospitals Contact

Professor Claire-Anne Siegrist, Director of the Center of Vaccinology

+41(22) 379 57 77

claire-anne.siegrist@unige.ch

 

HUG Media Contact

Nicolas de Saussure, PR Officer

+41 (22) 372 60 06

nicolas.desaussure@hcuge.ch

 

BioNet Contact

Laurent Dapremont, Director Strategic Business Development, BioNet-Asia

+66 (2) 361 8110

laurent.d@bionet-asia.com

www.bionet-asia.com

Download

BioNet-Asia Organized International Pertussis Symposium Celebrating its 15th Anniversary in Bangkok

Bangkok, Thailand, 21 April, 2017 – BioNet-Asia Co. Ltd organized the first International Symposium on Advances in Pertussis Immunisation in Bangkok, Thailand. The Symposium was attended by more than 300 international and Thai experts on pertussis vaccination as well as public health stakeholders, involving expert presentations and session chairing by world leaders on pertussis immunization including Prof. Stanley Plotkin (USA), Dr. Nicole Guiso (France), Prof. Terry Nolan (Australia), Prof. Keith Klugman (USA) and prominent public health leaders from Thailand including Prof. Teerapong Tantawichien and Prof. Tawee Chotpitayasundondh. The symposium coincided with BioNet’s 15th Anniversary, and the recent Marketing Approval of two of its new recombinant pertussis booster vaccines.

In his keynote presentation, Emeritus Prof. Stanley Plotkin (University of Pennsylvania, USA) discussed the reappearance of pertussis disease (whooping cough) in countries around the world and the need for new vaccine strategies and new vaccines to address this global problem. “The availability of a monovalent acellular pertussis vaccine could provide the medical community with a new way to approach pertussis immunization, especially in adolescents and pregnant women to protect their newborns” said Prof Plotkin. Western countries like Australia and USA that have been using acellular pertussis vaccines in their immunization programs since the late 90’s, have turned to recommending repeated pertussis booster vaccinations throughout life to control the spread of pertussis disease in their countries. “The protection induced by pertussis vaccines and infection is short-lived, so by keeping vaccine coverage high and revaccinating different age groups, France manages to decrease the incidence of the less than 6 months of age since 1996 “, Dr Nicole Guiso said, explaining why France still observes cycles of the disease but their intensity seems lower that those seen in other European countries. While it is mainly western countries that are reporting a rise in pertussis disease, the pertussis situation in low- and middle income countries (using whole cell pertussis vaccines) is largely unknown. “What we need are data from countries with a high uptake of whole-cell pertussis and this requires reliable surveillance systems to detect the burden of pertussis in neonatal deaths“, said Prof Keith Klugman, Director of Pneumonia at the Bill and Melinda Gates Foundation.

The Symposium was a perfect moment for BioNet to share data with the audience on two of its new pertussis vaccines, PertagenTM and BoostagenTM, produced using recombinant DNA technology, for which BioNet received Marketing Authorization Approval (MAA) from the Thai Food and Drug Administration for active booster immunization against pertussis in individuals from the age of 11 years onwards late December 2016. In her presentation Director of Clinical Development Dr. Simonetta Viviani (BioNet, Thailand) showed that in a Phase II/III clinical trial BioNet’s pertussis booster vaccines induced higher antibody responses compared to one of the currently available vaccines. “Other studies evaluating PertagenTM are planned in other countries. For example, a Phase II study is currently underway in Switzerland”, BioNet’s CEO Pham Hong Thai announced. Emeritus Prof. Piyasakol Sakolsatayadam, Minister of Public Health, Thailand, congratulated BioNet on this achievement: “I am very proud that a Thai company is making such a significant contribution to the pertussis world agenda”.

About BioNet-Asia
BioNet-Asia offers access to vaccine and technology through biotech innovation and partnering networks. BioNet has built several international partnerships fostering vaccine self-reliance and leading to the supply of billions of doses of vaccines worldwide. BioNet has also a broad pipeline of vaccines in R&D and clinical stages. BioNet-Asia’s pertussis vaccine is produced from a new proprietary Bordetella pertussis strain expressing genetically detoxified Pertussis Toxin (PTgen). The unique properties of BioNet PTgen enable the vaccine to induce superior anti-PT immune response. BioNet-Asia successfully demonstrated in a Phase II/III trial that its acellular pertussis vaccine (containing PTgen and FHA), as a monovalent or in combination, could significantly boost immunity against pertussis in adolescents and adults. For additional information, please visit www.bionet-asia.com.

BioNet Contact
Laurent Dapremont, Director Strategic Business Development, BioNet-Asia Co. Ltd.
+66 (2) 361 8110
laurent.d@bionet-asia.com
www.bionet-asia.com

Download

BioNet Received Thai FDA Approval of the World’s Only Available Recombinant Monovalent Acellular Pertussis (aP) Vaccine

BioNet’s vaccine is the first recombinant monovalent Pertussis vaccine in the world to receive a MAA for booster indication in adolescents and adults

Bangkok, December 23rd, 2016 - BioNet-Asia announced today that its first recombinant acellular Pertussis booster vaccine containing a proprietary genetically-detoxified Pertussis Toxin (PTgen), received Marketing Authorization Approval (MAA) from the Thai Food and Drug Administration.
The vaccine is indicated in individuals from the age of 11 years onwards for active booster immunization against pertussis, a highly contagious respiratory infection caused by Bordetella pertussis. There are 16 million pertussis cases worldwide each year.

Dr Jean Petre, Chief Scientific Officer and co-founder of BioNet said: “The approval of this innovative vaccine is the fruit of ten years of research on a new generation of recombinant pertussis vaccines to overcome the limitation of conventional acellular vaccines. BioNet’s recombinant DNA technology allows the production of a genetically-detoxified Pertussis Toxin (PTgen) without altering the structure of the epitopes of the Pertussis Toxin (PT). Therefore, induced antibodies can better recognize PT epitopes which results in an increased immune response to PT, as successfully demonstrated with PTgen-containing vaccines in comparative clinical studies.


In a clinical trial, 95% of adolescents immunized with BioNet’s aP vaccine seroconverted to PT (4-fold increase of antibody titer) compared to 55% vaccinated with a leading marketed Tdap vaccine. BioNet’s recombinant vaccine also induced significantly higher anti-PT neutralizing antibody titers.


With the pertussis disease re-emerging in many countries, the medical community is advocating for pertussis control strategies and the improvement of current vaccines. Conventional Tdap vaccines provide durable protection against diphtheria and tetanus but induce short-lived pertussis immunity,” indicated Professor Stanley Plotkin, Chairman of BioNet’s Scientific Advisory Board.


The availability of such a recombinant pertussis vaccine that induce higher initial antibody levels can address an unmet medical need. Having now a monovalent acellular pertussis vaccine can provide the healthcare professionals and policy makers with a new way to approach pertussis immunization, when only boosting pertussis immunity is sought, as for example in pregnant women to protect their newborns.

BioNet’s vaccine may be considered as an alternative to combined tetanus, diphtheria and acellular pertussis vaccines in persons having received multiple and frequent tetanus and diphtheria vaccine doses.


Mr Jacques-Francois Martin, Chairman of BioNet’s Strategic Advisory Board, added: “This MAA paves the way for further registration in other countries, especially where there is a resurgence of pertussis. New clinical studies in Europe and Asia-Pacific are ongoing or under planning to further evaluate BioNet’s monovalent vaccine but also other formulations of PTgen-containing vaccines.”


In the recent years, Pertussis has been resurgent in many countries and it is a major public health concern in USA, UK and Australia.

About BioNet
BioNet-Asia offers access to vaccine and technology through Biotech innovation and partnering networks. BioNet has built international partnerships, fostering vaccine self-reliance, and leading to the supply of billions of doses of vaccines. BioNet is also developing novel technologies to produce life-saving vaccines and has been granted a patent on new strains to express PTgen for the production of recombinant pertussis vaccines.

For further information, please contact:
Mr Laurent Dapremont
Director, Strategic Business Development
E-mail: laurent.d@bionet-asia.com
Tel: +61 (04) 1362 0839
www.bionet-asia.com

Download

DBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against Pertussis

DSMB expressed no safety concerns with Viaskin rPT 25 µg

Following positive DSMB review, dosing with Viaskin rPT 50 µg has been initiated

PARIS, BANGKOK & GENEVA--(BUSINESS WIRE)--DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), the Geneva University Hospitals (HUG) and BioNet-Asia Co. Ltd today announced that in a planned interim assessment of the Phase I trial of Viaskin rPT for booster immunization against Bordetella pertussis, the independent Data and Safety Monitoring Board (DSMB) concluded that there were no safety concerns with the administration of Viaskin rPT 25 ųg in the first subject cohort. Based on this review, enrollment in the trial has continued as planned, with dosing of Viaskin rPT 50 ųg commencing in the second subject cohort.

The Viaskin rPT pertussis booster vaccination program intends to test the ability of DBV’s needleless and adjuvant-free patch technology, Viaskin, to epicutaneously deliver two different doses of BioNet’s genetically detoxified, recombinant pertussis toxin for boosting immunity against whooping cough.

In the first dosing cohort, subjects received two applications of either Viaskin rPT 25 ųg or placebo. Following the DSMB’s positive recommendation, a second cohort of subjects will receive two applications of Viaskin rPT 50 ųg or placebo at two-week interval. This Phase I proof of concept study is being conducted under the supervision of Professor Claire-Anne Siegrist from the Clinical Research Center of HUG and is sponsored by DBV Technologies.

About the Phase I Viaskin rPT Trial

This Phase I dose-escalation, randomized, double-blind, placebo-controlled safety and immunogenicity study is assessing the safety of BioNet’s genetically-detoxified recombinant pertussis toxin administered by DBV’s Viaskin patches in 60 young healthy adults. Secondary endpoints will assess the patients’ humoral responses elicited by Viaskin rPT 25 μg and 50 μg compared to placebo. Immune cellular responses will also be monitored as exploratory endpoints.

The trial is being conducted in the Clinical Research Center of the Geneva University Hospitals. Men and women aged 18 to 40 years who have been vaccinated during childhood against pertussis will be randomized into two cohorts of 30 subjects each. The Viaskin patches will be applied for 48 hours, with a two-week interval between applications. Four weeks after the second Viaskin application, participants will receive one dose of Boostrix® dTpa vaccine to ensure the recall of immunity against diphtheria, tetanus and the three pertussis antigens (only a single antigen will be delivered through Viaskin rPT). All subjects will be observed after each application. Local and systemic adverse events will be monitored.

The first cohort has received two applications of Viaskin rPT 25 ųg or placebo. Following a positive DSMB review, dosing in the second patient cohort, which is expected to receive two applications of Viaskin rPT 50 ųg or placebo has commenced.

About Bordetella Pertussis

Pertussis, commonly known as whooping cough, is a highly contagious respiratory illness caused by a type of bacteria known as Bordetella pertussis. Pertussis vaccination is recommended as part of routine childhood immunization. Although the incidence of pertussis has declined as a result of immunization of infants and young children, vaccine-induced immunity does not persist for long. This phenomenon, known as waning immunity, has increased since the introduction of acellular pertussis vaccines in 1996, which tend to provide short-lived protection against the Bordetella pertussis bacteria. According to the U.S. Centers for Disease Control and Prevention (CDC), there are 16 million pertussis cases worldwide each year, mainly in adolescents and adults who often can infect infants who have not yet completed their pertussis immunization. In these young patients, pertussis can be severe and fatal.

Booster immunizations are now recommended for adolescents and adults, but compliance is not always high. A new vaccine technology that is patient-friendly, painless and non-invasive could help increase the compliance for booster immunization against whooping cough.

About DBV Technologies

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.

DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

About Geneva University Hospitals

The Geneva University Hospitals (HUG), reference academic institution at both national and international level, gather eight public hospitals of Geneva. Their centres of excellence cover hepato-biliary and pancreatic diseases, cardiovascular diseases, oncology, musculoskeletal and sports medicine, old age medicine, genetic medicine and vaccinology. Its Center of Vaccinology, led by Professor Claire-Anne Siegrist, gained international recognition through the performance of a large first-in-humans Phase I randomized clinical trial that enrolled 115 subjects to characterize the safety and immunogenicity of the VSV-ZEBOV Ebola vaccine candidate.

With their 10,500 employees, the HUG welcome each year 60,000 hospitalized patients and assure 91,000 emergencies, 990,000 consultations or ambulatory care and 26,000 surgical procedures. More than 800 physicians, 3,000 interns and 150 apprentices perform their training here. The HUG are working closely with the Faculty of Medicine of the University of Geneva and WHO in various training and research projects. They develop partnerships with CHUV, EPFL, CERN and other actors from the Lemanic Health Valley. More information on: www.hug-ge.ch

About BioNet-Asia

BioNet-Asia offers access to vaccine and technology through biotech innovation and partnering networks. BioNet has built several international partnerships fostering vaccine self-reliance and leading to the supply of billions of doses of vaccines worldwide. BioNet has also a broad pipeline of vaccines in R&D and clinical stages. BioNet most advanced program is the development of a new generation of pertussis vaccines aimed at overcoming the waning immunity observed with the conventional acellular pertussis vaccines.

BioNet’s pertussis vaccines are produced from a new proprietary Bordetella pertussis strain expressing genetically detoxified Pertussis Toxin (PTgen™). The unique properties of BioNet’s PTgen enables the vaccines to induce superior anti-PT immune response. For additional information, please visit www.bionet-asia.com

Forward Looking Statements

This press release contains forward-looking statements, including statements about the potential safety and efficacy of Viaskin as a means of delivering recombinant pertussis toxin to boost immunity against Bordetella pertussis. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. The Company’s product candidates have not been approved for sale in any jurisdiction. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, the Company’s Securities and Exchange Commission filings and reports, including in the Company’s Annual Report on Form 20-F for the year ended December 31, 2015 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.

 

Contacts

DBV Technologies
Susanna Mesa, +1-212-271-0861
Senior Vice President, Strategy
susanna.mesa@dbv-technologies.com
or
Media
Centron PR
Erinn White, +1-646-722-8822
ewhite@centronpr.com
or
Media Contact Europe
Alize RP, Relations Presse
Caroline Carmagnol, +33 (0)6 64 18 99 59
caroline@alizerp.com
or
Geneva University Hospitals
Professor Claire-Anne Siegrist, +41(22) 379 57 77
Director of the Center of Vaccinology
claire-anne.siegrist@unige.ch
or
HUG Media
Nicolas de Saussure, +41 (22) 372 60 06
PR Officer
nicolas.desaussure@hcuge.ch
or
BioNet
Laurent Dapremont, +66 (2) 361 8110
Director Strategic Business Development, BioNet-Asia Co. Ltd.
laurent.d@bionet-asia.com

Link

DBV Technologies, BioNet-Asia and the Geneva University Hospitals Initiate Phase I Study of Viaskin rPT for Pertussis Booster Vaccination

DBV Technologies, BioNet-Asia and the Geneva University Hospitals Initiate Phase I Study of Viaskin rPT for Pertussis Booster Vaccination

Proof of concept trial will evaluate the safety and immunogenicity of two doses of Viaskin rPT in healthy adults

Vaccine program to test Viaskin's needleless and adjuvant-free patch technology in reactivating pertussis toxin immunity

PARIS, BANGKOK and GENEVA September 6, 2016 - DBV Technologies (Euronext: DBV - ISIN: FR0010417345 -Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, the Geneva University?Hospitals (HUG) and BioNet-Asia Co. Ltd today announced that the first subject has been enrolled in a proof of concept Phase I clinical trial testing Viaskin rPT in the reactivation of immunity against Bordetella pertussis (whooping cough) in healthy adults. This pertussis vaccination program intends to test the ability of DBV's needleless and adjuvant-free patch technology, Viaskin, to epicutaneously deliver two doses of BioNet's genetically detoxified, recombinant pertussis toxin (rPT) to boost immunity against whooping cough. The Phase I proof of concept study is being conducted under the supervision of Professor Claire-Anne Siegrist from the Clinical Research Center of HUG and is being sponsored by DBV Technologies.

Dr. Pierre-Henri Benhamou, Chairman and Chief Executive Officer of DBV Technologies, said: "Utilizing the skin's immune properties for vaccination is a paradigm shift in this field. Professor Siegrist and her team recently?published a paper with pre-clinical data showing that a single application of Viaskin rPT on intact skin was capable of reactivating whooping cough immunity without the use of adjuvants. This valuable collaboration with HUG and BioNet has the potential to be a breakthrough in vaccinations; if Professor Siegrist and her team can replicate the in vivo results in humans, Viaskin rPT could be the first non-invasive and self-administrable vaccine to be developed for boosting pertussis immunity." Dr. Benhamou continued, "Our commitment to developing transformational products that can improve lives drives our innovation strategy at DBV. Enthusiasm for our unique patient-centric approach to immunotherapy was recently captured by the fast enrollment of our Viaskin Phase III trial in peanut allergy. As in food allergies, our focus in vaccines is to develop novel products that can address unmet medical?needs in an effective and safe way. We are excited to launch the rPT program, which continues to highlight the strengths and versatility of our Viaskin technology platform."

A significant increase in the prevalence of pertussis, a highly contagious respiratory illness, has been reported in a number of countries around the world, and it is associated with increased mortality in young infants. Pertussis vaccination is recommended as part of routine childhood immunization, but the immunity acquired through vaccination or infection is short-lived, and its maintenance requires repeated boosting at regular time points.Viaskin's novel epicutaneous delivery technology may offer a more convenient, needleless and adjuvant-free option for boosting pertussis immunization.

Professor Claire-Anne Siegrist, Director of the Center of Vaccinology of HUG, said: "We know that regular boosters are needed to maintain protection against pertussis, and our preclinical studies showed that the reactivation of immune memory may be achieved using Viaskin. We are eagerly looking forward to assessing whether this is similarly effective in humans, as the possibility of using needleless and adjuvant-free booster vaccines would be a change of paradigm in our approach to the prevention of pertussis and of other vaccine preventable diseases."

Dr. Pham Hong Thai, Chief Executive Officer of BioNet-Asia, said: "Given the safety and superior immunogenicity of our recombinant acellular pertussis vaccine as it was demonstrated in a Phase II/III trial, we are excited to explore alternative delivery options for BioNet's proprietary genetically inactivated pertussis toxin. This promising collaboration with DBV and HUG could be the first step to offering a needle-free recombinant pertussis booster vaccine, and it shows our commitment to deliver innovative solutions for controlling the resurgence of pertussis around the globe."

About the Phase I Viaskin rPT Trial
A Phase I dose-escalation, randomized, double-blind, placebo-controlled safety and immunogenicity study will assess the safety of BioNet's genetically-detoxified rPT administered by DBV's Viaskin patches in 60 young healthy adults. Secondary endpoints will assess the patients' humoral responses elicited by Viaskin rPT 25 ?g and 50 ?g compared to placebo. Immune cellular responses will also be monitored as exploratory endpoints.

The trial will take place in the Clinical Research Center of HUG. Men and women aged 18-40 years who have been vaccinated during childhood against pertussis will be randomized into two cohorts of 30 subjects each. The first cohort will receive two applications of Viaskin rPT 25 ?g or placebo. The Viaskin patches will be applied for 48 hours, with a two-week interval between applications. Four weeks after the second Viaskin application, participants will receive one dose of Boostrix? dTpa vaccine to ensure the recall of immunity against diphtheria, tetanus and the three pertuss is antigens (only a single antigen will be delivered through Viaskin rPT). All subjects will be observed after each application. Local and systemic adverse events will be monitored.

The safety and tolerability of the first dose of Viaskin rPT 25 ?g will be analyzed before initiating treatment in the second patient cohort, which is expected to receive two applications of Viaskin rPT 50 ?g or placebo, and analysis of the results will follow the same study design as in the Viaskin rPT 25 ?g cohort.

About Bordetella Pertussis
Pertussis, commonly known as whooping cough, is a highly contagious respiratory illness caused by a type of bacteria known as Bordetella pertussis. Pertussis vaccination is recommended as part of routine childhood immunization. Although the incidence of pertussis has declined as a result of immunization of infants and young children, vaccine -induced immunity does not persist for long. This phenomenon, known as waning immunity, has increased since the introduction of acellular pertussis vaccines in 1996, which tend to provide short-lived protection against the Bordetella pertussis bacteria. According to the U.S. Centers for Disease Control and Prevention (CDC), there are 16 million pertussis cases worldwide each year, mainly in adolescents and adults who often can infect infants who have not yet completed their pertussis immunization. In
these young patients, pertussis can be severe and fatal.?Booster immunizations are now recommended for adolescents and adults, but compliance is not always high. A new vaccine technology that is patient-friendly, painless and non-invasive could help increase the compliance for booster immunization against whooping cough .

About DBV Technologies
DBV Technologies is developing Viaskin?, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT?, DBV's method of delivering biologically active compounds to the immune system through intact skin. Wi th this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV?s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its pl atform in vaccines and other immune
diseases.

DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

About Geneva University Hospitals
The Geneva University Hospitals (HUG), reference academic institution at both national and international level, gather eight public hospitals of Geneva. Their centres of excellence cover hepato-biliary and pancreatic diseases, cardiovascular diseases, oncology, musculoskeletal and sports medicine, old age medicine, genetic medicine and vaccinology. Its Center of Vaccinology, led by Professor Claire-Anne Siegrist, gained international recognition through the performance of a large first in-humans Phase I randomized clinical trial that enrolled 115 subjects to characterize the safety and immunogenicity of the VSV-ZEBOV Ebola vaccine candidate.

With their 10,500 employees, the HUG welcome each year 60,000 hospitalised patients and assure 91,000 emergencies, 990,000 consultations or ambulatory care and 26,000 surgical procedures. More than 800 physicians, 3,000 interns and 150 apprentices perform their training here. The HUG are working closely with the Faculty of Medicine of the University of Geneva and WHO in various training and research projects. They develop partnerships with CHUV, EPFL, CERN and other actors from the Lemanic Health Valley. More information on: www.hug-ge.ch

About BioNet-Asia
BioNet-Asia offers access to vaccine and technology through biotech innovation and partnering networks. BioNet has built several international partnerships fostering vaccine self-reliance and leading to the supply of billions of doses of vaccinesworldwide. BioNet has also a broad pipeline of vaccines in R&D and clinical stages. BioNet most advanced program is the development of a new generation of pertussis vaccines aimed at overcoming the waning immunity observed with the conventional acellular pertussis vaccines.

BioNet pertussis vaccine is produced from a new proprietary Bordetella pertussis strain expressing genetically detoxified Pertussis Toxin (rPT). The unique properties of BioNet rPT enables the vaccine to induce superior anti-PT immune response. BioNet has successfully demonstrated in a Phase II/III trial that its recombinant acellular pertussis vaccine (containing rPT and FHA), as standalone or in combination, could significantly boost immunity against pertussis in adolescents and adults. For additional information, please visit www.bionet-asia.com

Forward Looking Statements
This press release contains forward-looking statements, including statements about the potential safety and efficacy of Viaskin as a means of delivering recombinant pertussis toxin to boost immunity against Bordetella pertussis. These forward-looking statements are not promises or guarantees and in volve substantial risks and uncertainties. The Company's product candidates have not been approved for sale in any jurisdiction. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial
results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorit? des March?s Financiers, the Company's Securities and Exchange Commission filings and reports, including in the Company's Annual Report on Form 20-F for the year ended December 31, 2015 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forwardlooking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future event s or circumstances or otherwise.

DBV Technologies Contact
Susanna Mesa
Senior Vice President, Strategy
+1 212-271-0861
susanna.mesa@dbv-technologies.com

Media Contact
Erinn White, Centron PR
+1-646-722-8822
ewhite@centronpr.com

Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
caroline@alizerp.com

Geneva University Hospitals Contact
Professor Claire-Anne Siegrist, Director of the Center of Vaccinology
+41(22) 379 57 77
claire-anne.siegrist@unige.ch

HUG Media Contact
Nicolas de Saussure, PR Officer
+41 (22) 372 60 06
nicolas.desaussure@hcuge.ch

BioNet Contact
Laurent Dapremont, Director Strategic Business Development, BioNet-Asia Co. Ltd.
+66 (2) 361 8110
laurent.d@bionet-asia.com

Download

BioNet-Asia announces the formation of its Scientific Advisory Board

BioNet-Asia announces the formation of its Scientific Advisory Board

BioNet Announces the Appointment of Dr. Stanley Plotkin as Chairman of the Scientific Advisory Board


Paris, France - BioNet-Asia, an innovative clinical stage vaccine company announced the formation of BioNet Scientific Advisory Board (SAB), under the chairmanship of Emeritus Prof. Dr. Stanley Plotkin. The mission of BioNet SAB will be to provide valuable scientific advice, along with strategic guidance on its recombinant pertussis vaccine pipeline while the company is advancing rapidly with its clinical development.

The following members, well-known experts in the field of pertussis vaccinology, were appointed during BioNet first Scientific Advisory Board meeting held in Paris on March 3rd, 2016:

- Chairman of the Scientific Advisory Board - Dr. Stanley Plotkin, Emeritus Professor of Wistar Institute and University of Pennsylvania, developed the rubella vaccine now used worldwide and has worked extensively on the development and application of other vaccines including polio, rabies, varicella, rotavirus and cytomegalovirus. Dr Plotkin has held senior positions at the Epidemic Intelligence Service, U.S. Public Health and with Sanofi Pasteur. He wrote over 700 articles, and has edited several books including Vaccines, now the standard textbook in the field.

- Prof. Claire-Anne Siegrist is the Director of the Center of Vaccinology of the University Hospitals of Geneva (Switzerland), and Head of the WHO Collaborating Center for Vaccine Immunology. She is also an advisor to committees for immunization in Switzerland, the UK and WHO (Strategic Advisory Group of Experts), including for Pertussis Vaccines. Professor Siegrist has contributed to a large number of scientific publications in the field of infectious diseases and vaccine immunology.

- Dr. Nicole Guiso is the former Head of the Institut Pasteur Research Unit, Molecular Prevention and Therapy of Human Diseases, Paris (France), and Director of the French National Center of Reference for Pertussis and other bordetelloses and for toxinogenic corynebacteria. She was an advisor to the Pertussis and Diphtheria working groups of the French committee for immunization and was appointed as expert of the WHO Strategic Advisory Group of Experts working group on Pertussis Vaccines. Dr Guiso wrote over 300 articles in the field of infectious diseases.

"We are honored to welcome such eminent scientists to our advisory board to support BioNet pertussis clinical development programs," said Pham Hong Thai, the Chief Executive Officer of BioNet. Dr Stanley Plotkin commented: "I am pleased to chair the Scientific Advisory Board of BioNet and to support BioNet in developing a new generation of pertussis vaccines which has the potential to control the resurgence of pertussis in the world."

About BioNet-Asia
BioNet-Asia is a clinical-stage biotech company with a focus on technological innovation and global market access. BioNet is developing a broad pipeline of recombinant vaccines in its state-of-the-art facilities in Thailand. BioNet's first genetically-engineered pertussis vaccines are now being evaluated in Phase II/III clinical trials. The company has also built global manufacturing alliances leading to the supply of billions of doses of vaccines worldwide.


For further information, please contact:
BioNet-Asia Co., Ltd.
Mr Laurent Dapremont
Director, Strategic Business Development
E-mail: info@bionet-asia.com
www.bionet-asia.com

Download

Vaccine Global Access a priority as DCVMN Annual Conference concludes

Bangkok, Thailand, October 8th, 2015 -The 16th AGM and Annual Conference of the Developing Countries Vaccine Manufacturers Network (DCVMN) came to a close today after four days of productive interactions between more than 300 stakeholders.

Co-hosted by the Queen Saovabha Memorial Institute (QSMI) of the Thai Red Cross Society and BioNet-Asia, the conference gathered an unprecedented number of participants comprising vaccines manufacturers, private and public research organizations, public health and not-for-profit ONG's, suppliers and government officials.

When interviewed on the role of the Thai Ministry of Public Health with the current challenges of developing vaccines for global health Dr. Supamit Chunsuttiwat, Senior Expert in Preventive Medicine, Ministry of Public Health, Thailand indicated that: "The Ministry of Public Health is not only providing vaccines and vaccination to the people especially children, it develops comprehensive policies in consultation with other countries, and through the Thai Food and Drug Administration (FDA), it ensures the proper development, production and registration of quality vaccines for the country. Another important role of the Ministry is to provide support to the growing Thai vaccine production."

Dr Supamit also stressed that: "we will need at least regional collaboration to secure vaccine supply for the region. Some countries are getting more self-reliant like Indonesia and Vietnam, and through regional planning and coordination, we might be able to produce sufficient vaccines and be able to supply some vaccines for the whole region."

The organizers were particularly pleased with the good collaborating spirit transpiring from the various panels and interactive sessions as well as by the quality of the presentations and the breadth of topics covered.

Dr. Jerome Kim, Director General, International Vaccine Institute (IVI) explained how IVI contributes to Vaccine Global Access. "IVI's mission is to discover, develop and deliver safe, affordable, effective vaccines for global health".

Dr Kim illustrated the role that IVI takes in vaccine global access: "The oral cholera vaccine was used this year in 3 campaigns. The first in Ethiopia, the second in Malawi in the setting of an epidemic, and then in in Nepal, where the government of Korea and several significant private donors in Korea contributed funding to do emergency vaccination campaigns in Nepal to prevent cholera, and we were able to do a very effective campaign, 95% uptake in the second dose of vaccine in these earthquake-stricken districts. So increasingly working internationally for certain vaccines is a critical part of what we do."

Beyond key lectures and panel discussion, the conference also offered training workshops organized by the World Health Organization and industry leading suppliers. It was also the opportunity for attendants to visit state-of-the-art vaccine manufacturing facilities at QSMI and BioNet-Asia.

About DCVMN

DCVMN is an international alliance of manufacturers aiming to protect people against known and emerging infectious diseases globally by increasing the availability and enhancing the quality of vaccines produced in emerging countries. www.dcvmn.org

About QSMI

The Queen Saovabha Memorial Institute of the Thai Red Cross Society is an institute producing BCG vaccine, equine Rabies Immunoglobulins and snake antivenoms. QSMI is also a World Health Organization Collaborating Center for research on Rabies and venomous snakes. www.saovabha.com

About BioNet

BioNet-Asia is a clinical-stage biotech company with a focus on technological innovation and global market access. The company is building up global partnerships, leading to the production of billions of doses of vaccines worldwide. www.bionet-asia.com

Download

Focus on International Cooperation for Global Access to Vaccines at the DCVMN 16th Annual AGM.

Bangkok, Thailand, October 6th, 2015 - Under the auspices of the Queen Saovabha Memorial Institute (QSMI) of the Thai Red Cross Society and BioNet-Asia, the 16th Annual General Meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN) kicked off this week in Bangkok, Thailand.

Mr. Phan Wannamethee, Secretary General of the Thai Red Cross Society, opened the conference by reminding that
"The DCVMN's ultimate goal is in harmony with the philosophy of the Thai Red Cross Society in the relief of disasters, promotion of welfare, and elimination of diseases." He then "commended members of DCVMN for their efforts to reach the common goal of protecting people against infectious diseases with better vaccines for a better quality of life."

The conference includes key lectures and sessions with organizations like UNICEF, PAHO, VPPAG and IAIM. Dr. Jean-Marie Okwo-Bele, Director of WHO's Department of Immunization, Vaccines and Biologicals presented the Global Vaccine Action Plan (GVAP) and fascinating data on the progresses achieved, as well as the gaps and challenges ahead to attain these goals. Dr. Okwo-Bele explained how WHO helps accelerate research that will lead to vaccine licensure and vaccine policy and indicated that: "WHO convenes the best experts in the world to look at vaccines that are available, and to look at the evidence around those vaccines so we can understand how these vaccines can be used in developing countries".

Several other key organizations such as CHAI, PATH and BMGF are also well represented at the conference. Dr. Peter Khoury, Senior Program Officer, The Bill & Melinda Gates Foundation indicated that: "The Gates Foundation supports research and development of vaccines particularly in developing countries, and it supports access to vaccines against preventable diseases for people in the poorest parts of the world. The basis for this belief is that all people deserve the chance to lead a healthy, productive life which is supported by DCVM's supplying of high quality, low cost vaccines".

About DCVMN
DCVMN is an international alliance of manufacturers aiming to protect people against known and emerging infectious diseases globally by increasing the availability and enhancing the quality of vaccines produced in emerging countries. www.dcvmn.org

About QSMI
The Queen Saovabha Memorial Institute of the Thai Red Cross Society is an institute producing BCG vaccine, equine Rabies Immunoglobulins and snake antivenoms. QSMI is also a World Health Organization Collaborating Center for research on Rabies and venomous snakes. www.saovabha.com

About BioNet
BioNet-Asia is a clinical-stage biotech company with a focus on technological innovation and global market access. The company is building up global partnerships, leading to the production of billions of doses of vaccines worldwide. www.bionet-asia.com

Download

Bangkok to host International Vaccine Manufacturers Conference QSMI and BioNet to co-host 16th AGM of DCVMN October 5th, 2015

The Queen Saovabha Memorial Institute, the Thai Red Cross Society and BioNet-Asia are the co-hosts of the Organizing Committee of the 16th Annual General Meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN) under the theme of "Quality Vaccine for all". The meeting is to be held from the 5th to 7th of October 2015 at the Centara Grand at Central World in Bangkok, Thailand.

The DCVMN is a nonprofit international alliance of vaccine manufacturers founded in the year 2000 and aiming to protect people against known and emerging infectious diseases globally by increasing the availability, and enhancing the quality of vaccines produced in developing countries. The network includes today 44 vaccine manufacturers in 16 countries, producing and supplying over 200 products and 40 products are WHO Prequalified.

Prof. Sumana Khomvilai, Deputy Director of QSMI said: "On behalf of the DCVMN AGM 2015 Organizing Committee, we are pleased to welcome all delegates to the conference. We hope the meeting will be a unique opportunity to address the challenges related to vaccine production and procurement."?
Indeed, world vaccine experts including from the World Health Organization UNICEF, Bill & Melinda Gates Foundation, GAVI, PATH and PAHO will gather to discuss vaccine demand, supply shortage and vaccine security, while a panel of speakers will also present novel technologies to develop new vaccines against infectious diseases such as chikungunya, dengue, pertussis and cholera.

During the opening ceremony, Dr Mahendra Suhardono, President of DCVMN, also emphasized the important role of DCVMs in the global efforts to eradicate poliomyelitis disease by supplying OPV vaccines for immunization programs. He also called for a cooperation spirit and close interaction among WHO, UNICEF, DCVM, and all relevant eradication initiatives in order to contribute to the success of polio eradication in the world.


About DCVMN
DCVMN is an international alliance of manufacturers aiming to protect people against known and emerging infectious diseases globally by increasing the availability and enhancing the quality of vaccines produced in emerging countries. The network includes today 44 vaccine manufacturers, in 16 countries, producing and supplying over 40 different types of vaccines. www.dcvmn.org


About QSMI
The Queen Saovabha Memorial Institute of the Thai Red Cross Society is an institute producing BCG vaccine, equine Rabies Immunoglobulins and snake antivenoms, using the latest technology and equipment. QSMI is also a World Health Organization Collaborating Center for research on Rabies and venomous snakes. www.saovabha.com

About BioNet
BioNet-Asia is a clinical-stage biotech company with a focus on technological innovation and global market access. BioNet is developing recombinant Pertussis and Dengue vaccines. The company has also built up global partnerships, leading to the production of billions of doses of vaccines worldwide. www.bionet-asia.com

Download

Key Scientific Data Demonstrating that Epicutaneous Administration May Reactivate Protective Immunity against Pertussis in an experimental model published in Vaccine (2015)

PARIS, BANGKOK and GENEVA, 10 June 2015 - DBV Technologies Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT, a clinical-stage specialty biopharmaceutical company, the University of Geneva (UNIGE) and BioNet-Asia Co. Ltd announced today the publication of key scientific data in Vaccine demonstrating the potential usefulness of the Viaskin technology to boost protective immunity against Bordetella pertussis (whooping cough). This preclinical in vivo, proof-of-concept experiment shows that a single application of DBVs' Viaskin delivering BioNet's rPT (recombinant Pertussis Toxin) alone or in combination with pertactin and filamentous hemagglutinin effectively reactivated vaccine-induced pertussis immunity and protects against Bordetella pertussis.

DBV Technologies, UNIGE and BioNet-Asia are currently preparing a proof-of-concept Phase 1 clinical trial with a pertussis boosting vaccine using DBV's Viaskin patch technology, which allows the epicutaneous delivery of antigens without adjuvants, loaded with BioNet's genetically-inactivated rPT. It is anticipated that this Phase 1 trial will assess the safety and immunogenicity of Viaskin rPT in 60 young adults. This trial is expected to be performed under the supervision of Pr. Claire-Anne Siegrist of UNIGE and sponsored by DBV. The proof of concept trial is expected to start in the first quarter of 2016.

Dr. Pierre-Henri Benhamou, Chairman and CEO of DBV Technologies, said: "We would like to congratulate the scientists of the three teams for their outstanding preclinical achievement. This data demonstrates the potential efficacy of the Viaskin technology to develop a pertussis boosting vaccine without requiring any needles or adjuvants. The growing incidence of pediatric pertussis cases advocates for the need of periodic boosters that would be facilitated by convenient and adjuvant-free vaccines." Dr. Benhamou continued, "Viaskin's epicutaneous delivery mechanism enables us to deliver optimized antigens such as BioNet's genetically-detoxified Pertussis Toxin, which could generate a better tolerated and more efficacious booster vaccine product."

Pr. Claire-Anne Siegrist, Director of the Center of Vaccinology of the University of Geneva said: "It is remarkable that a single application of Viaskin coated with 3 pertussis antigens on intact skin was capable of reactivating protective immunity against a pathogen as complex as pertussis. Should this be observed in humans, it could tremendously facilitate the administration of this vaccine as frequent boosters are needed to maintain protection at the highest level."

Dr. Pham Hong Thai, CEO of BioNet-Asia, said: "These results are consistent with the preclinical and clinical results of BioNet-Asia recombinant acellular pertussis vaccine when administered through traditional delivery. I am very happy to see this data published in the public scientific domain. We are eager to continue this exciting collaboration with DBV and the University of Geneva to open the prospect for a needle free recombinant pertussis vaccine."

In order to mimic the human conditions under which vaccine-induced memory cells persist while antibodies disappear, the experiment featured in Vaccine used a novel adoptive transfer murine model in which immune splenocytes were transferred to syngeneic recipients prior to immunization and/or challenge. The data showed that a single 48-hour application of Viaskin delivering rPT, pertactin and filamentous hemagglutinin on the intact skin of primed mice effectively triggers the reactivation of vaccine-induced memory B cells into plasma cells producing high titers of anti-PT IgG1 and IgG2a antibodies and protecting against intranasal challenge with live B. pertussis. Thus, combining the use of an optimally immunogenic rPT and Viaskin, a novel epicutaneous delivery system, enabled reactivating protective pertussis immunity using an adjuvant-free, needleless, patient-friendly technology.

This scientific publication, entitled "Needle-free and adjuvant-free epicutaneous boosting of pertussis immunity: preclinical proof of concept", is available online in Vaccine: http://ac.els-cdn.com/S0264410X15007628/1-s2.0-S0264410X15007628-main.pdf?_tid=d811c4a6-0e97-11e5-b4b3-00000aacb35e&acdnat=1433848283_beca05adb892343d43cc6efefb92adde

About Pertussis

Pertussis, commonly known as "whooping cough", is a very contagious respiratory illness caused by a type of bacteria called Bordetella pertussis. Pertussis vaccination is recommended as part of routine childhood immunization. Although the incidence of pertussis has declined through the immunization of infants and young children, vaccine-induced immunity does not persist long. This phenomenon of "waning immunity" was accentuated by the introduction of acellular pertussis vaccines in 1996. According to the U.S. Centers for Disease Control and Prevention (CDC), there are 16 million pertussis cases worldwide each year, mainly in adolescents and adults who often then pass on the disease to infants who have not yet completed their pertussis immunization series, and in whom pertussis is most severe. Consequently, booster immunizations are now recommended to adolescents and adults, especially those in contacts with young infants. A new technology - user friendly and non-invasive- using a recombinant pertussis vaccine could help increase the compliance required for these booster vaccinations.

About DBV Technologies
DBV Technologies is developing Viaskin, an innovative new approach to the treatment of allergies - a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin Peanut and Viaskin Milk. The clinical development program for Viaskin Peanut has received Fast Track designation and Breakthrough Therapy designation from the U.S. Food and Drug Administration.
DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

About University of Geneva
Founded in 1559 by Jean Calvin and Theodore de Beze, the University of Geneva is the second largest Haute ecole in Switzerland and is amongst the top 100 best universities in the world. The institution enjoys worldwide recognition and is highly opened to the world. Every year the University welcomes around 16 000 students in its eight faculties teaching science, medecine, humanities, social and economic sciences, law, theology, psychology and educational sciences, translation and interpreting. The University of Geneva has three missions: education, research and knowledge-sharing. The University has been a member of the League of European Research-intensive Universities since 2002. www.unige.ch

About BioNet-Asia
BioNet-Asia is an independent vaccine company with a focus on technological innovation and market access. BioNet has built several strategic alliances fostering vaccine self-reliance leading to the production and supply of billions of doses of vaccines worldwide. In its vaccine manufacturing plant in Thailand, BioNet is developing a broad pipeline of vaccines in R&D and clinical stages, such as recombinant Pertussis, CRM197 protein carrier, Dengue and Hepatitis B vaccines. The company has successfully transferred the technology in Asia to produce Hib meningitis vaccine which is now commercialized and pre-qualified as a pentavalent vaccine. BioNet has also filed a patent application for a new Recombinant Acellular Pertussis Vaccine that has been shown safe and highly immunogenic in a Phase I/II study. BioNet has several collaborations with first-class biopharmaceutical companies, vaccine manufacturers and academic organizations around the globe. For additional information about the company, please visit www.bionet-asia.com

Forward Looking Statement related to DBV Technologies
This press release contains forward-looking statements, including statements about the potential safety and efficacy of Epicutenaous Immunotherapy (EPIT). These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. The Company's product candidates have not been approved for sale in any jurisdiction. Among the factors that could cause actual results to differ materially from those described or projected herein are uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorite des Marches Financiers, the Company's Securities and Exchange Commission filings and reports, including in the Company's Annual Report on Form 20-F for the year ended December 31, 2014 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.

DBV Technologies contacts:

Nathalie Donne, Director, Corporate Communication & Business Development, Tel. : +33(0)1 55 42 78 72, nathalie.donne@dbv-technologies.com
Susanna Mesa, VP Finance, US Investor Relations & Strategy, Tel. : +1 917-346-3447, susanna.mesa@dbv-technologies.com

DBV Technologies US Media Contacts
Marion Janic, Rooney & Associates, Tel. : +1-212-223-4017, mjanic@rooneyco.com

University of Geneva contact:
Prof. Claire-Anne Siegrist, Director of the Center of Vaccinology. Tel: +41(22) 379 57 77. claire-anne.siegrist@unige.ch

BioNet contact:
Pham Hong Thai, CEO, BioNet-Asia Co. Ltd. Tel: +66 (2) 361 8110. Email: info@bionet-asia.com

Download

BioNet strengthens advisory board with appointment of vaccine veteran Jacques-Francois Martin

BioNet-Asia appoints Jacques-Francois Martin to its advisory board as it moves its Recombinant Pertussis vaccine into Phase II/III.

Lyon, France, December 19th, 2014 - BioNet-Asia (BioNet), a vaccine company focused on innovative vaccine discovery and supply, announced that vaccine senior executive Jacques-Francois Martin was joining its Advisory Board effective January 1st.

"Jacques-Francois is a highly respected executive in the world of vaccine and evidence of the commercial successes he has led are too many to mention. I am glad that BioNet will benefit from his tremendous experience and knowledge, and I am personally looking forward to working with him again" said Pham Hong Thai, BioNet-Asia CEO.

Martin has spent a lifetime in the pharmaceutical and biotech industries. He is the founder and CEO of Parteurop Pharma, a French consulting firm and has been board member of several life sciences companies and organizations such as the International AIDS Vaccine Initiative. He was also the CEO of Pasteur Merieux Connaught (now Sanofi-Pasteur) and Biocine (now part of Novartis Vaccines) before becoming President and CEO of The Vaccine Fund, an organization working together with GAVI (Global Alliance for Vaccines and Immunization) to provide life saving vaccines to low-income countries.

"I am delighted to join BioNet's Advisory Board in such an exciting time for the company. BioNet is uniquely positioned to develop and bring to market innovative and cost-effective vaccines to the developing world. BioNet's recombinant acellular pertussis is one of the most promising vaccines in its class and I am really looking forward to helping to develop the partnerships required to deliver such life-saving vaccines to the neediest" said Martin.

For nearly ten years, BioNet has been working on the development of a new Recombinant Pertussis (RP) vaccine which has recently shown to be safe and immunogenic in humans. BioNet proprietary genetically-engineered non-toxic Pertussis Toxin induces a higher level of neutralizing antibody than conventional vaccines, and thus it could enhance a better protective immunity against pertussis which currently wanes rapidly with some acellular pertussis vaccines.

About BioNet-Asia
BioNet-Asia is an independent vaccine company with a focus on technological innovation and product supply. BioNet has a successful track record in product development partnership, technology transfer and global market access. In its manufacturing plant in Thailand, BioNet has a broad pipeline of vaccines in R&D and clinical stages, such as Recombinant Pertussis and combined vaccines. Bionet has transferred its Hib meningitis vaccine technology for the manufacturing of a full liquid pentavalent vaccine, and it has recently entered into a production partnership for producing a new Rabies vaccine. BioNet has also built several strategic alliances fostering vaccine self-reliance and leading to the production and supply of billions of doses of vaccines worldwide.

For further information, please contact:
BioNet-Asia Co., Ltd.
Mr. Supachai Nampornchaisakul
Tel: +66 2361 8110
E-mail: info@bionet-asia.com
www.bionet-asia.com

Download

BioNet provides update on Recombinant Pertussis vaccine at BioJapan 2014

Yokohama, Japan, October 15th, 2014 - BioNet-Asia's CEO and Managing Director, Dr Pham Hong Thai provided today an update on the company lead vaccine program in his presentation at BioJapan 2014. Dr Pham said that the current Phase I/II trial in Thailand showed that the vaccine is safe and immunogenic and full results will soon be published in a peer reviewed journal. BioNet Recombinant Acellular Pertussis vaccine will enter clinical Phase II/III in 2015.

Many licensed acellular pertussis vaccines have been associated to a resurgence of pertussis in developed countries. All these vaccines are inactivated by the use of chemicals which denature Pertussis Toxin, the principal antigen present in acellular vaccines. BioNet's third-generation Pertussis vaccine is using a genetically-inactivated or recombinant Pertussis Toxin (rPT) which?overcomes the limitations of the chemically-detoxified acellular vaccines. Hence, BioNet Recombinant Pertussis vaccine could potentially be the solution to the re-emergence of pertussis.

Download

Asian manufacturers to bring new Rabies vaccine (2014)

Queen Saovabha Memorial Institute, BioNet-Asia and Liaoning Cheng Da Biotechnology jointly announce a collaboration to manufacture the next generation Rabies vaccine in Thailand.

Download

BioNet to enter a collaboration with DBV and University of Geneva on a Phase 1 study of Recombinant Acellular Pertussis vaccine delivered by Viaskin patch (2013)

DBV Technologies (Euronext Paris: DBV), creator of Viaskin, announced today that it has entered into a collaboration agreement with BioNet-Asia Co. Ltd and the University of Geneva (UNIGE) to work on a whooping cough (pertussis) booster vaccine. The clinical proof of concept product candidate will combine BioNet's unique recombinant non-toxic Pertussis Toxin (rPT) with DBV's Viaskin technology, which allows for the epicutaneous delivery of the antigen without any adjuvant.

The DBV-BioNet-UNIGE research and development collaboration will consist of a non-clinical component and a clinical development program. The Non-Clinical Study Program will measure the specific immunity and protective responses elicited by a Viaskin pertussis antigens boost in a Bordetella pertussis respiratory murine model. The Clinical Study Program will be initiated in the second half of 2014 to evaluate the boosting influence of recombinant non-toxic pertussis toxin delivered by Viaskin in a Phase I, proof-of-concept, study performed under the responsibility of Pr. Siegrist from the University of Geneva, Switzerland. This Phase I clinical trial will assess the safety and immunogenicity of Viaskin-PT and evaluate the humoral and cellular responses in healthy adults.

Download

BioNet to license recombinant pertussis strain (2012)

BioNet-Asia Co Ltd, a vaccine-focused biotech company based in Thailand has announced today the signature with a China-based company of a binding letter of intent to license a Bordetella pertussis strain, genetically modified to express antigens that can be used in the development of acellular pertussis-based vaccines.

Acellular Pertussis Vaccines are now routinely and successfully used to prevent whooping cough disease, in Western Europe, North America, Japan and Korea but not in the emerging countries because of the high cost.

The advantages of the recombinant pertussis strain producing very high yields of inactivated pertussis toxins enable the production of a recombinant Acellular Pertussis Vaccine to be affordable in China and other developing countries.

Mr Vitoon Vonghangool, Managing Director of BioNet-Asia said, this is an important milestone because it is the outcome of years of research and development in Thailand.

Our company has been heavily affected by the floods in October 2011 and it was important to find a partner interested in our recombinant pertussis strain. We expect to receive double-digit million dollars over a period of 10 years followed by royalties. Upfront payments are expected within this year and will be used to reconstruct our facilities.

Dr Pham Hong Thai, Managing Director of BioNet-Asia concluded that "The agreement will be signed within a couple of months and we are also in discussion with some vaccine manufacturers for collaboration on recombinant acellular pertussis based vaccines."

BioNet to enter Hepatitis B vaccine production (2012)

Could become the only company in the world to produce both recombinant acellular pertussis and recombinant Hepatitis B vaccines

BioNet-Asia Co., Ltd., the only privately-owned biotech company in Thailand focusing on the development, manufacturing and supply of vaccines, has acquired the technology for producing Hepatitis B vaccine with the ultimate goal to produce it locally.

Mr. Vitoon Vonghangool, Managing Director of BioNet-Asia, confirmed that following the recent changes by the government to prioritize the local production of Hepatitis B Vaccine (HBV) over acellular pertussis vaccine (aP), the company decided to acquire HBV technology.

It is an important milestone for the company but also for our country, because Hepatitis B vaccine is included in the national immunization program. Several organizations have worked on this vaccine or have wished to produce it, but, so far, no local HBV has been made available. We have given the utmost priority to this project, and indeed a team is being trained in Europe right now. Meanwhile, we are evaluating various locations in Thailand to apply the technology with the objectives to produce the first development batches in the second semester of this year, said Mr Vitoon.

Despite being affected by the mega-floods at the end of last year, BioNet-Asia has decided to initiate several vaccine collaborations and projects. More scientists are being recruited to work on new R&D or technology projects, and international experts are also joining the company to lead the upcoming industrial projects.

BioNet to enter development of Dengue vaccine (2011)

BioNet-Asia Co Ltd, a vaccine-focused biotech company based in Thailand has announced today the signature of a license agreement on chimeric Dengue virus strains between BioNet, National Science and Technology Development Agency (NSTDA), Chiang Mai University and Mahidol University. BioNet will receive the Dengue strains for further development with the goal to produce a Dengue vaccine.

Dengue, a mosquito-borne disease is caused by four different Dengue viruses (serotypes 1-4) and has spread rapidly during the last 20 years. Dengue now affects most of tropical Asia and the Americas resulting in tens of millions of cases of severe Dengue fever world-wide annually with 500,000 persons, mostly children, hospitalized with Dengue hemorrhagic fever. No specific treatment or vaccine is available.

Mr Vitoon Vonghangool, Managing Director of BioNet-Asia said, this agreement on Dengue strains is a welcomed example of how public and private sectors can collaborate more closely and share their expertise in the vaccine research and development. For the last 30 years, Thailand has been at the forefront in the research for Dengue vaccines and we are committed to pursue the development. Indeed we are now completing the construction of a new facility that will host the development and testing of the Dengue vaccine candidate.?

Thailand to accelerate vaccine development and production capability (2011)

Gears to reduce vaccine import and penetrate ASEAN countries?

In celebrating its 10th Anniversary, BioNet-Asia Co., Ltd., the only privately-owned vaccine research and development company in Thailand, incorporation with the National Vaccine Institute organized a symposium today on 'Building Vaccine Development Capacity in Thailand' to encourage more public-private partnerships (PPP) to accelerate local vaccine development and production to reduce vaccine import and consumer costs and to meet domestic and ASEAN demand when the ASEAN Economic Community (AEC) materializes.

"Our company has had many years of experience in the vaccine business, and our mission is to produce affordable vaccines, and make them available not only locally, but also to other ASEAN countries. We would, therefore, like to stimulate all concerned to seek ways on how best to accelerate local vaccine development and production to bridge the huge vaccine gap between industrialized and developing worlds", commented Mr. Vitoon Vonghangool, Managing Director of BioNet-Asia Co., Ltd.

First R&D Centre to develop recombinant acellular pertussis vaccine in Thailand opens (2009)

BioNet-Asia Co., Ltd. today opened the first Thai private R&D Center and vaccine pilot plant dedicated to the development of bacterial vaccines in Thailand, located in the Hi-Tech Industrial Estate of Ayudhaya. The opening ceremony was presided over by Dr. Jean Petre, an eminent vaccine expert, internationally recognized for his work in pediatric vaccines, and attended by both industry-related guests and media.

Our company has had many years of experience in the vaccine business, and, therefore, we recently embarked in the development of innovative vaccines. The opening of our R&D centre shows our commitment to bridge the huge vaccine gap between industrialized and developing worlds by delivering new and affordable vaccines to emerging countries, revealed Mr. Vitoon Vonghangool, Managing Director of BioNet-Asia Co., Ltd.

BioNet's facilities are situated on 17 rai of land, and have been designed and built in compliance with the International and WHOs Good Manufacturing Practices (GMP) standard. The R&D Center occupies an area of 2,000 square meters, comprising of quality-control laboratories and the Bio Safety Level 2+ development lab, equipped with fermentation and purification units.